<DOC>
	<DOCNO>NCT00220480</DOCNO>
	<brief_summary>The primary objective multicenter study evaluate efficacy escitalopram treatment resistant depression ( TRD ) , assess 2 consecutive fail antidepressant treatment different class . The last treatment receive 6 week prospective trial venlafaxine .</brief_summary>
	<brief_title>A Naturalistic Study Efficacy Safety Escitalopram Treatment Resistant Depression</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Any patient meet follow criterion eligible inclusion Prospective phase I study : 1 . The patient able read understand patient information sheet . 2 . Prior screening procedure , patient must sign informed consent form . No studyrelated procedure may perform patient sign form . 3 . The patient outpatient , male female . 4 . The patient 18 65 year age . 5 . The patient suffers diagnosis recurrent Major Depressive Disorder ( current episode assess MINI ) , moderate severe , accord DSMIVTR criterion ( classification code = 296.3x ) . 6 . The patient total score 22 high MADRS . 7 . The patient treat current episode antidepressant ( escitalopram venlafaxine ) prescribe continuously optimal dose ( see table Appendix 1 ) least 4 week precede selection ( AD1 ) . 8 . The investigator considers switch treatment venlafaxine ( AD2 ) , prescribe optimal dose , define study protocol . Any patient meet one follow criterion include screen phase study : 1 . The patient previously participate study . 2 . Results blood sample selection show antidepressant prescribe ( AD1 ) , plasma concentration expect threshold accord time last intake . 3 . The patient take another antidepressant combination antidepressant he/she consider nonresponder ( AD1 ) . 4 . The patient one follow condition : 1 . Any current psychiatric disorder establish principal diagnosis Major depressive episode define DSMIVTR ( assess MINI ) . 2 . Any Substance disorder ( except nicotine caffeine ) within previous 6 month define DSMIVTR . 3 . Any severe personality disorder accord investigator clinical judgement , might compromise study . 5 . The patient us disallow recent concomitant medication within specified time period : 1. oral antipsychotic drug within 2 month depot antipsychotic preparation within past 6 month . 2 . ECT within past 6 month . 3. lithium , carbamazepine , valproate valpromide within past month . 4. benzodiazepine dose high 10 mg diazepam equivalent , within last week . 5. nonbenzodiazepine anxiolytic within last week . 6. serotonin agonist within last week . 7. drug potential psychotropic effect within last week . 8. drug know low blood pressure last week . 6 . The patient treat investigational product within 3 month prior screen . 7 . The patient treat current episode escitalopram venlafaxine . 8 . The patient history severe drug allergy hypersensitivity , know hypersensitivity escitalopram venlafaxine . 9 . The patient start ( start ) formal psychotherapy month precede inclusion . 10 . The patient previous history convulsive disorder single childhood febrile seizure . 11 . The patient present evidence urinary retention glaucoma . 12 . The patient serious illness and/or serious sequela thereof , include liver renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological , infectious , neoplastic , metabolic disturbance . 13 . The patient , opinion investigator , basis physical examination , medical history vital sign , comorbid condition ( ) would render inclusion study unsafe . 14 . The patient take medication , opinion investigator , could interfere assessment safety , tolerability , efficacy . 15 . The patient , opinion investigator , unlikely comply clinical study protocol unsuitable reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>